[go: up one dir, main page]

FR2419072A1 - Nouvelles compositions pharmaceutiques a base d'un peptide monocyclique - Google Patents

Nouvelles compositions pharmaceutiques a base d'un peptide monocyclique

Info

Publication number
FR2419072A1
FR2419072A1 FR7904989A FR7904989A FR2419072A1 FR 2419072 A1 FR2419072 A1 FR 2419072A1 FR 7904989 A FR7904989 A FR 7904989A FR 7904989 A FR7904989 A FR 7904989A FR 2419072 A1 FR2419072 A1 FR 2419072A1
Authority
FR
France
Prior art keywords
pharmaceutical compositions
compositions based
monocyclic
new pharmaceutical
monocyclic peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7904989A
Other languages
English (en)
Other versions
FR2419072B1 (fr
Inventor
Thomas Cavanak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25690510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2419072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CH246178A external-priority patent/CH636013A5/de
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of FR2419072A1 publication Critical patent/FR2419072A1/fr
Application granted granted Critical
Publication of FR2419072B1 publication Critical patent/FR2419072B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet des compositions pharmaceutiques à base de peptides monocycliques. Selon l'invention, ces compositions pharmaceutiques contiennent un peptide monocyclique actif du point de vue pharmacologique et un support comprenant au moins l'une des compositions suivantes : a. un ester non ionique d'un triglycéride et d'un polyalkylènepolyol, b. un triglycéride d'un acide gras saturé, et c. un mono- ou diglycéride. Ces compositions pharmaceutiques améliorent la résorption des peptides monocycliques.
FR7904989A 1978-03-07 1979-02-27 Nouvelles compositions pharmaceutiques a base d'un peptide monocyclique Granted FR2419072A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH246178A CH636013A5 (en) 1978-03-07 1978-03-07 More readily absorbable pharmaceutical composition
CH863478 1978-08-14

Publications (2)

Publication Number Publication Date
FR2419072A1 true FR2419072A1 (fr) 1979-10-05
FR2419072B1 FR2419072B1 (fr) 1983-04-22

Family

ID=25690510

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7904989A Granted FR2419072A1 (fr) 1978-03-07 1979-02-27 Nouvelles compositions pharmaceutiques a base d'un peptide monocyclique

Country Status (27)

Country Link
US (1) US4388307A (fr)
JP (1) JPS54132223A (fr)
AR (1) AR223667A1 (fr)
AT (1) AT375828B (fr)
AU (1) AU528714B2 (fr)
CA (1) CA1139667A (fr)
CY (1) CY1285A (fr)
DD (1) DD142149A5 (fr)
DE (1) DE2907460A1 (fr)
DK (1) DK154539C (fr)
ES (1) ES478295A1 (fr)
FI (1) FI65914C (fr)
FR (1) FR2419072A1 (fr)
GB (1) GB2015339B (fr)
HK (1) HK48585A (fr)
IE (1) IE48016B1 (fr)
IL (1) IL56790A (fr)
IT (1) IT1115038B (fr)
KE (1) KE3516A (fr)
MY (1) MY8500134A (fr)
NL (2) NL187260C (fr)
NO (2) NO152635C (fr)
NZ (1) NZ189819A (fr)
PH (1) PH15159A (fr)
PT (1) PT69309A (fr)
SE (1) SE445174B (fr)
SG (1) SG14785G (fr)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034567B1 (fr) * 1980-02-14 1984-11-07 Sandoz Ag Procédé de synthèse totale des cyclosporines ainsi que les nouvelles cyclosporines
DE3224619A1 (de) * 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
EP0127426A1 (fr) * 1983-05-23 1984-12-05 Takeda Chemical Industries, Ltd. Compositions pharmaceutiques percutanées pour application externe
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4727035A (en) * 1984-11-14 1988-02-23 Mahoney Walter C Immunoassay for cyclosporin
US4576645A (en) * 1984-12-06 1986-03-18 Block Drug Co., Inc. Whipped gel composition
JPS61280435A (ja) * 1985-04-04 1986-12-11 Kanji Takada サイクロスポリン類のリンパ指向性製剤
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
JP2574354B2 (ja) * 1986-05-02 1997-01-22 ブリガム・アンド・ウイメンズ・ホスピタル 脂肪酸含有成分およびサイクロスポリンよりなる腎毒性の減少した組成物
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
GB8717300D0 (en) * 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
DE3851152T2 (de) * 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
AU620048B2 (en) * 1987-09-03 1992-02-13 University Of Georgia Research Foundation, Inc., The Ocular cyclosporin composition
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
DE3830494B4 (de) * 1987-09-15 2006-05-18 Novartis Ag Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
HU205010B (en) * 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
CA1326995C (fr) * 1988-01-29 1994-02-15 Kozo Kurihara Compositions a base de cyclosporines
CH679119A5 (fr) * 1988-05-13 1991-12-31 Sandoz Ag
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GR1000466B (el) * 1989-01-28 1992-07-30 Sandoz Ag Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
JP3631490B2 (ja) 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5637317A (en) * 1992-05-18 1997-06-10 Dietl; Hans Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
DE59310166D1 (de) * 1992-05-18 2001-05-31 Ciclomulsion Ag Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
SK277092A3 (en) * 1992-09-07 1996-08-07 Galena As Medicaments with n-methylated cyclic undecapeptides
PT589843E (pt) 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
PT649651E (pt) 1993-09-28 2001-03-30 Scherer Gmbh R P Preparacao de capsulas de gelatina macia
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
NZ270145A (en) * 1994-03-01 1996-08-27 Lilly Co Eli Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent
ES2137516T3 (es) * 1994-06-01 1999-12-16 Yuhan Corp Composicion a base de ciclosporina y su procedimiento de fabricacion.
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
JPH10504291A (ja) * 1994-07-22 1998-04-28 ジー．ディー．サール アンド カンパニー 自己乳化性ドラッグデリバリーシステム
AU715165B2 (en) 1994-11-03 2000-01-20 Novartis Ag Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them
US5603951A (en) * 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
KR100239799B1 (ko) * 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US6696413B2 (en) * 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
SE504582C2 (sv) * 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
RU2172183C2 (ru) * 1995-08-25 2001-08-20 Сангстат Медикал Корпорейшн Оральные циклоспориновые составы
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
SI9620014A (sl) * 1995-08-25 1998-04-30 Sangstat Medical Corporation Oralne oblike ciklosporina
DE19549852B4 (de) 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
US5798333A (en) * 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
EP1331002A3 (fr) 1997-01-30 2004-01-14 Novartis AG Compositions pharmaceutiques exemptes d'huile, à base de cyclosporine A
SI0969856T1 (en) * 1997-03-12 2005-06-30 Abbott Laboratories Hydrophilic binary systems for the administration of cyclosporine
CA2285983A1 (fr) 1997-04-29 1998-11-05 Bernard Charles Sherman Preconcentre pour emulsion contenant une cyclosporine et un monoglyceride acetyle
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
IN188719B (fr) * 1997-09-08 2002-11-02 Panacea Biotec Ltd
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6028067A (en) * 1997-12-05 2000-02-22 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
KR19990047897A (ko) * 1997-12-05 1999-07-05 김충환 사이클로스포린 함유 약학적 조성물
RU2257917C2 (ru) * 1998-12-11 2005-08-10 Фармасолюшнз, Инк. Самоэмульгирующиеся композиции для плохорастворимых в воде лекарственных препаратов
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
ES2251985T3 (es) * 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP1273287A1 (fr) * 2000-04-04 2003-01-08 Shionogi & Co., Ltd. Compositions huileuses contenant des medicaments solubles dans des graisses
WO2001097832A1 (fr) * 2000-06-21 2001-12-27 Audit Institute For Medical Services And Quality Assurance Gmbh Preparations pharmaceutiques contenant des cylosporines et des huiles neutres
ATE370744T1 (de) 2000-09-18 2007-09-15 Rpg Life Sciences Ltd Selbstemulgierende formulierung mit erhöhter bioverfügbarkeit und immunsupprimierender wirkung
OA12619A (en) * 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
WO2003004098A1 (fr) 2001-07-06 2003-01-16 Sucampo Ag Composition pour administration directe comprenant un inhibiteur de l'interleukine 2 et un agent antimicrobien
RU2317067C2 (ru) * 2001-10-19 2008-02-20 Изотехника Инк. Микроэмульсионный предконцентрат аналога циклоспорина
EP1458405A1 (fr) * 2001-11-21 2004-09-22 Sucampo AG Utilisation de fk506 et d'analogues de celui-ci pour traiter des maladies allergiques
CA2471241A1 (fr) * 2001-12-20 2003-07-03 Bernard Charles Sherman Compositions pharmaceutiques comprenant une cyclosporine, un tensioactif hydrophile et un tensioactif lipophile
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
GB2391473B (en) * 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391472B (en) * 2002-08-02 2004-12-08 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20040150061A1 (en) * 2003-01-30 2004-08-05 Hsin Chung Hsien Package structure of a photosensor
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
NZ547389A (en) 2003-11-21 2009-11-27 Combinatorx Inc Combinations of a compound such as ibudilast and a corticosteroid for the treatment of inflammatory disorders
DE102004038980A1 (de) * 2004-08-10 2006-02-23 Cognis Deutschland Gmbh & Co. Kg Antibeschlagmittel für Kunststoffe
EP1811979B1 (fr) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Microcapsules comprenant methylxanthine et un corticosteroide
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
EP1885342B8 (fr) 2005-03-21 2016-06-22 Teva Czech Industries s.r.o. Inhibiteur de cristallisation et son utilisation dans des capsules de gelatine
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) * 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US8911777B2 (en) * 2007-04-04 2014-12-16 Sigmoid Pharma Limited Pharmaceutical composition of tacrolimus
JP2010525929A (ja) * 2007-05-04 2010-07-29 アラーガン、インコーポレイテッド 眼内レンズを用いる患者の処置におけるシクロスポリンの使用
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
TW200932240A (en) * 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
SG172894A1 (en) * 2009-01-08 2011-08-29 Allergan Inc Cyclosporine compositions for enhancing nail growth
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20110009339A1 (en) 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
EP2432455B1 (fr) 2009-05-18 2014-11-12 Sigmoid Pharma Limited Composition comprenant des gouttes d'huile
MA33491B1 (fr) 2009-07-07 2012-08-01 Boehringer Ingelheim Int Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP4338750A3 (fr) 2011-03-11 2024-05-15 Beth Israel Deaconess Medical Center Inc. Anticorps anti-cd40 et leurs utilisations
EP2763650A2 (fr) 2011-10-05 2014-08-13 Allergan, Inc. Composition pour améliorer la santé des ongles
CA2851346A1 (fr) 2011-10-05 2013-04-11 Allergan, Inc. Compositions pour ameliorer la sante des ongles
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
WO2016205423A2 (fr) 2015-06-15 2016-12-22 Lipocine Inc. Composition et méthode pour l'administration orale de promédicaments androgènes
DK3307322T3 (da) 2015-09-04 2021-04-19 Primatope Therapeutics Inc Humaniserede anti-cd40-antistoffer og anvendelser deraf
WO2017047299A1 (fr) * 2015-09-15 2017-03-23 富士フイルム株式会社 Composition liquide pour injection
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CA3107214A1 (fr) 2018-07-20 2020-01-23 Lipocine Inc. Maladie du foie
WO2020242862A1 (fr) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Formulations injectables à libération prolongée et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2108007A1 (fr) * 1970-09-26 1972-05-12 Organon Nv

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) * 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
GB1110875A (en) * 1964-12-11 1968-04-24 Glaxo Lab Ltd Compositions containing procaine penicillins
FR94740E (fr) * 1967-10-25 1969-10-24 Rhone Poulenc Sa Nouveaux cyclopeptides et leur préparation.
ES396746A1 (es) * 1971-11-06 1974-12-01 Gallardo Antonio Sa Nuevo procedimiento de fabricacion de suspensiones establesidoneas para antibioticos.
CH574247A5 (en) * 1972-02-17 1976-04-15 Ciba Geigy Ag Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
JPS4891218A (fr) * 1972-03-06 1973-11-28
AR207116A1 (es) * 1973-03-28 1976-09-15 Ciba Geigy Ag Procedimiento para preparar nuevas dotriacontapeptidoamidas
DE2463138C2 (de) * 1973-12-06 1984-07-05 Sandoz-Patent-GmbH, 7850 Lörrach Das Antibiotikum Cyclosporin B (S 7481/F-2), seine Herstellung und Verwendung
GB1547164A (en) * 1975-08-14 1979-06-06 Beecham Group Ltd Veterinary compositions
CH614931A5 (fr) * 1975-11-04 1979-12-28 Sandoz Ag
DE2555481C3 (de) * 1975-12-10 1985-10-03 Sandoz-Patent-GmbH, 7850 Lörrach Herstellung stabiler Tropflösungen von hydrierten Ergotalkaloiden
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2108007A1 (fr) * 1970-09-26 1972-05-12 Organon Nv

Also Published As

Publication number Publication date
IE790704L (en) 1979-09-07
CY1285A (en) 1985-07-05
HK48585A (en) 1985-06-28
PT69309A (fr) 1979-04-01
US4388307A (en) 1983-06-14
IL56790A0 (en) 1979-05-31
CA1139667A (fr) 1983-01-18
AT375828B (de) 1984-09-10
DK154539B (da) 1988-11-28
DK154539C (da) 1989-05-16
SE7901683L (sv) 1979-09-08
KE3516A (en) 1985-04-19
IE48016B1 (en) 1984-09-05
NZ189819A (en) 1984-05-31
FI790640A7 (fi) 1979-09-08
GB2015339B (en) 1982-09-15
JPS54132223A (en) 1979-10-15
DE2907460C2 (fr) 1990-09-27
AU4486279A (en) 1979-09-13
IT1115038B (it) 1986-02-03
DK86079A (da) 1979-09-08
FR2419072B1 (fr) 1983-04-22
AU528714B2 (en) 1983-05-12
NL930135I1 (nl) 1993-11-01
FI65914B (fi) 1984-04-30
NO152635B (no) 1985-07-22
SG14785G (en) 1985-08-16
PH15159A (en) 1982-08-24
NO790661L (no) 1979-09-10
ATA163779A (de) 1984-02-15
JPS627891B2 (fr) 1987-02-19
ES478295A1 (es) 1979-05-16
IL56790A (en) 1982-01-31
FI65914C (fi) 1984-08-10
IT7948152A0 (it) 1979-02-27
NO1994028I1 (no) 1994-12-28
SE445174B (sv) 1986-06-09
NL7901703A (nl) 1979-09-11
NO152635C (no) 1985-10-30
NL187260C (nl) 1991-08-01
DE2907460A1 (de) 1979-09-13
AR223667A1 (es) 1981-09-15
GB2015339A (en) 1979-09-12
DD142149A5 (de) 1980-06-11
MY8500134A (en) 1985-12-31

Similar Documents

Publication Publication Date Title
FR2419072A1 (fr) Nouvelles compositions pharmaceutiques a base d'un peptide monocyclique
BE901737A (fr) Composition pharmaceutique pour le traitement de l'ischemie myocardique aigue.
ATE197121T1 (de) Duschöl
ATE215370T1 (de) Selbstemulgierende formulierung enthaltend lipophile verbindungen
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
DK0658097T3 (da) Deodoriserende kosmetiske midler med et indhold af fedtsyrer
KR940018343A (ko) 트리글리세라이드
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
FR2601259B1 (fr) Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives.
FR2453649A1 (fr) Composition pharmaceutique a action prolongee contenant des acides biliaires utile notamment pour la lyse des calculs
KR880007069A (ko) 트리글리세라이드 조성물
AR223950A1 (es) Composicion insecticida sinergizada,que contiene como ingredientes activos(+)trans-crisantemato de(+-)2-alil-3-metil-ciclopent-2-en-1-on-4-ilo y (+)cis o(+)trans-crisantemato de n-(3,4,5,6-tetrahidroftalimido)-metilo
ES479691A1 (es) Procedimiento para la preparacion de 1,3-diesteres de acido benzoico del 17 alfa-etinil-7 alfa-metil-1,3,5(10) estra- trien -1,3,17 beta-triol.
FR2414336A1 (fr) Nouvelles compositions pharmaceutiques a base de prostaglandines
FR2375865A1 (fr) Compositions medicamenteuses contenant des sterolines et leurs applications therapeutiques
CO4960657A1 (es) Composicion farmaceutica
KR970010742A (ko) 프로스타글란딘 유도체
NO932843L (no) Farmasoeytiske preparater
FR2453648A1 (fr) Nouvelles compositions pharmaceutiques a base d'une quinazolinone exercant une action analgesique et d'un agent myotonolytique
BE793210A (fr) Esters d'acides thiophosphoriques utilisables notamment comme matieres actives de produits phytopharmaceutiques
JPS5350141A (en) Stabilization of prostaglandin and prostaglandin analogues
SE8800988D0 (sv) Pharmaceutical compositons acting on the heart and cardiovascular system and process for preparing same
FR2361387A1 (fr) Composition dermatologique
SE8104657L (sv) Injicerbara farmaceutiska kompositioner
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation

Legal Events

Date Code Title Description
CL Concession to grant licences
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0167, 920507

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0167, 790227

CL Concession to grant licences
TP Transmission of property